InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
12
T+90 hit rate
44%
T+90 mean return
-1.7%
Across 34 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by DeLong Mark Jeffrey, Chief Business & Strat Officer. Officer active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Cumulatively, 48 disclosures have been recorded. Breakdown: 0 buy · 12 sells. Total volume traded: €1.5m. History available since 18 May 2021. The latest transaction was filed on 11 February 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations48 total
114,591 sharesCommon StockSEC:0001193125-26-224597
114,591 sharesCommon StockSEC:0001193125-26-224597:0
▼
363 shares@ US$28.53880.4% of flowCommon StockSEC:0001127602-25-004328:0
▼
365 shares@ US$29.52360.5% of flowCommon StockSEC:0001127602-25-002373:0
▼
1,396 shares@ US$30.42551.8% of flowCommon StockSEC:0001127602-25-001831:0
▼
1,235 shares@ US$29.95821.6% of flowCommon StockSEC:0001127602-25-001616:0
28,508 shares0Common StockSEC:0001127602-25-001616:1
▼
1,599 shares@ US$28.70212.0% of flowCommon StockSEC:0001127602-25-001185:0
◇
5,201 shares@ US$13.852.9% of flowCommon StockSEC:0001127602-24-022070:0
▼
9,913 shares@ US$56.9022.9% of flowCommon StockSEC:0001127602-24-010605:0
▼
597 shares@ US$67.76691.7% of flowCommon StockSEC:0001127602-24-004711:0
▼
367 shares@ US$64.13821.0% of flowCommon StockSEC:0001127602-24-002734:0
▼
1,384 shares@ US$64.9963.7% of flowCommon StockSEC:0001127602-24-001931:0
16,963 shares0Common StockSEC:0001127602-24-001438:0
▼
131 shares@ US$46.03620.3% of flowCommon StockSEC:0001127602-23-026187:0
5,280 shares0Common StockSEC:0000899243-23-005788:0
●
670 shares@ US$51.211.4% of flowCommon StockSEC:0001127602-23-005137:0
●
367 shares@ US$52.770.8% of flowCommon StockSEC:0001127602-23-002674:0
●
1,149 shares@ US$52.052.4% of flowCommon StockSEC:0001127602-23-002126:0
19,634 shares0Common StockSEC:0001127602-23-001492:0
196 shares@ US$58.000.5% of flowCommon StockSEC:0001127602-22-024301:0
5,000 shares@ US$15.523.4% of flowCommon StockSEC:0001127602-22-021302:0
5,000 shares@ US$15.523.3% of flowCommon StockSEC:0001127602-22-020885:0
5,000 shares@ US$15.523.4% of flowCommon StockSEC:0001127602-22-020734:0
5,000 shares@ US$64.5014.0% of flowCommon StockSEC:0001127602-22-020734:1
25 of 48 declarations
About DeLong Mark Jeffrey
Mark Jeffrey DeLong is the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc.
